Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells
- PMID: 31840972
- DOI: 10.1021/acsami.9b15803
Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells
Abstract
Five peptide ligands of four different cell surface receptors (nucleolin, CXCR1, CMKLR1, and CD44v6) have been evaluated as targeting moieties for triple-negative human breast cancers. Among them, the peptide F3, derived from phage display, promotes the fast and efficient internalization of a genetically fused green fluorescent protein (GFP) inside MDA-MB-231 cancer stem cells in a specific receptor-dependent fashion. The further engineering of this protein into the modular construct F3-RK-GFP-H6 and the subsequent construct F3-RK-PE24-H6 resulted in self-assembling polypeptides that organize as discrete and regular nanoparticles. These materials, 15-20 nm in size, show enhanced nucleolin-dependent cell penetrability. We show that the F3-RK-PE24-H6, based on the Pseudomonas aeruginosa exotoxin A (PE24) as a core functional domain, is highly cytotoxic over target cells. The combination of F3, the cationic peptide (RK)n, and the toxin domain PE24 in such unusual presentation appears as a promising approach to cell-targeted drug carriers in breast cancers and addresses selective drug delivery in otherwise difficult-to-treat triple-negative breast cancers.
Keywords: cancer stem cells; nucleolin; self-assembling polypeptides; targeting; triple-negative breast cancer.
Similar articles
-
Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.Bioconjug Chem. 2020 Oct 21;31(10):2421-2430. doi: 10.1021/acs.bioconjchem.0c00482. Epub 2020 Sep 30. Bioconjug Chem. 2020. PMID: 32996763
-
A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.Clin Cancer Res. 2011 Jan 1;17(1):100-10. doi: 10.1158/1078-0432.CCR-10-1303. Epub 2010 Nov 12. Clin Cancer Res. 2011. PMID: 21075824
-
Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.Toxins (Basel). 2016 Jul 25;8(8):217. doi: 10.3390/toxins8080217. Toxins (Basel). 2016. PMID: 27463727 Free PMC article.
-
A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.FEBS J. 2011 Dec;278(23):4683-700. doi: 10.1111/j.1742-4658.2011.08182.x. Epub 2011 Jun 2. FEBS J. 2011. PMID: 21585657 Free PMC article. Review.
-
Stealth and mimicry by deadly bacterial toxins.Trends Biochem Sci. 2006 Feb;31(2):123-33. doi: 10.1016/j.tibs.2005.12.007. Epub 2006 Jan 6. Trends Biochem Sci. 2006. PMID: 16406634 Review.
Cited by
-
Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).Int J Mol Med. 2023 Sep;52(3):81. doi: 10.3892/ijmm.2023.5284. Epub 2023 Jul 21. Int J Mol Med. 2023. PMID: 37477132 Free PMC article. Review.
-
Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal Transduct Target Ther. 2024 Jul 5;9(1):170. doi: 10.1038/s41392-024-01851-y. Signal Transduct Target Ther. 2024. PMID: 38965243 Free PMC article. Review.
-
A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer.J Adv Res. 2023 Dec;54:271-292. doi: 10.1016/j.jare.2023.02.005. Epub 2023 Feb 14. J Adv Res. 2023. PMID: 36791960 Free PMC article. Review.
-
NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs.Cancers (Basel). 2020 Jul 10;12(7):1861. doi: 10.3390/cancers12071861. Cancers (Basel). 2020. PMID: 32664322 Free PMC article.
-
M2 macrophage microvesicle-inspired nanovehicles improve accessibility to cancer cells and cancer stem cells in tumors.J Nanobiotechnology. 2021 Nov 27;19(1):397. doi: 10.1186/s12951-021-01143-5. J Nanobiotechnology. 2021. PMID: 34838042 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
